Clin2
NCT06649214Possibly a fitNot yet recruiting

Study of a new schizophrenia medication tablets

Schizophrenia

Treatments studied

Part of Mental health clinical trials.

This trial tests a new combination tablet (olanzapine-samidorphan) for adults with schizophrenia. It aims to see if it helps control symptoms while potentially reducing weight gain, which can be a side effect of some schizophrenia medicines.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
654 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You are between 18 and 55 years old.
  • Your body mass index (BMI) is between 18 and 30 (this is a measure of weight relative to height).
  • You have been diagnosed with schizophrenia by a doctor.
  • Your schizophrenia symptoms are at least moderately severe (measured by a standard rating scale).
  • You have not taken certain antipsychotic medicines (olanzapine, clozapine, chlorpromazine, thioridazine) in the last 6 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05303064Recruiting· Phase 3
Study of weight gain medicine for teens with certain mood or psychosis

This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.

Dothan, Alabama
NCT06821945Recruiting· Phase 2
Olanzapine dosing study for schizophrenia

This trial tests a slower, lower-dose schedule of the drug olanzapine for people with schizophrenia. It aims to see if a gentler start is safer and works as well, especially for those who may need less medication due to other health conditions.

Daegu
NCT06923891Not yet recruiting· Phase 4
Testing a new pill for early schizophrenia

This trial tests a new combination pill (xanomeline/trospium) for people who started treatment for schizophrenia in the last 5 years, to see if it helps better than their current medicine. You would stop your current antipsychotic and switch to this study drug under close doctor supervision.

Richmond, Texas
NCT06740890Recruiting· Phase 4
Exercise and a new medication for schizophrenia or bipolar disorder

This study tests whether a combination of a daily medication (olanzapine-samidorphan) and a structured exercise program can help people with schizophrenia, schizoaffective disorder, or bipolar disorder improve their health and well-being.

New York, New York
NCT06517199Recruiting· Phase 3
Olanzapine for cancer-related appetite and weight loss

This trial tests whether the drug olanzapine can help improve appetite and reduce weight loss in people with advanced cancer who are not currently receiving chemotherapy or other anti-cancer treatment. It may be an option if you have lost weight and have little appetite.

Bangkok
NCT05705492Recruiting· Phase 2
Olanzapine to help cancer-related weight and appetite loss

This Phase 2 trial tests whether olanzapine can help people with advanced cancer who are losing weight and not eating enough. It looks for improvements in appetite and weight while you receive your first-line palliative cancer treatment.

Portland, Oregon

Hear when a new Schizophrenia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.